Join the movement
We can change the trajectory of colorectal cancer together.

Seeking collaborative researchers
Project Cure CRC is a multi-faceted effort combining innovative research and cutting-edge venture philanthropy. Ending colorectal cancer will take all of us, in collaboration, driving urgently toward cures.
Direct funding
Project Cure CRC’s fund for breakthoughs supports science from a wide variety of researchers.
Young Investigator Accelerator Award
Supports early-career faculty with innovative ideas in CRC research, providing up to $200,000 over two years for original preclinical, translational, or early clinical projects.
Senior Investigator Accelerator Award
Funds transformative research to advance CRC therapies, offering up to $500,000 over two years for senior investigators proposing localized or metastatic CRC projects.
Pilot Accelerator Award
Encourages high-risk, high-reward CRC research with clear hypotheses, providing up to $200,000 over two years to establish proof-of-concept.
Team Science Accelerator Award
Supports collaborative, multidisciplinary CRC research teams with up to $500,000 over two years to drive curative science and innovation.
Opportunistic Award
Provides up to $500,000 for small startup companies (with one or less rounds of funding) conducting novel CRC research over one year to advance curative science.
Innovators wanted
Project Cure CRC prioritizes high-risk/high-reward proposals that fast-track research toward curative solutions, with a strong preference for collaborative and public-private partnerships.
Sponsors
Up Next
Funded researchTop resources

Project Cure CRC Continues to Fuel Urgently Needed Research Funding
The Alliance's Project Cure CRC announces $1.3 million in new research grants — bringing total funding to nearly $12 million — to drive breakthroughs in colorectal cancer care and address critical research gaps.

2025 ASCO update: Six big studies
The 2025 ASCO Annual Meeting featured several important studies that could change how colorectal cancer is treated, including a pivotal study for BRAF V600E patients.